Shares of Axovant Sciences nearly doubled in value after the dementia drug developer said its initial public offering raised $315 million, more than Axovant had expected.
British-based drugmaker GlaxoSmithKline opted Wednesday to keep its stake in its stand-alone HIV business as it set out its strategy following a big deal with Switzerland's Novartis.
British drugmaker AstraZeneca PLC plans to spend about $260 million on Omthera Pharmaceuticals Inc., a specialty drug developer with only 14 employees but has a potential treatment for patients who have high levels of fats ...
The conservative government of Prime Minister Tony Abbott on Wednesday said it would press ahead with the sale of Australia's largest health insurer Medibank Private via an initial public offering.
(AP)—Shares of respiratory drug maker KaloBios Pharmaceuticals are inching higher on the first day of trading.
Shares of cancer drug developer Adaptimmune fell Wednesday after the British company's initial public offering raised $191.3 million.
Shares of Adamas Pharmaceuticals rose Thursday after the drug developer's initial public offering raised $48 million.